{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:31:13Z","timestamp":1762101073098},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s10165-010-0347-x","type":"journal-article","created":{"date-parts":[[2010,9,3]],"date-time":"2010-09-03T06:53:28Z","timestamp":1283496808000},"page":"1-9","source":"Crossref","is-referenced-by-count":17,"title":["Peroxisome proliferator-activated receptor gamma in osteoarthritis"],"prefix":"10.1093","volume":"21","author":[{"given":"Hassan","family":"Fahmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanne","family":"Martel-Pelletier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,9,4]]},"reference":[{"key":"347_CR1","first-page":"2199","volume-title":"Arthritis and allied conditions. a textbook of rheumatology","author":"J Martel-Pelletier","year":"2005","unstructured":"Martel-Pelletier J, Lajeunesse D, Pelletier JP. Etiopathogenesis of osteoarthritis. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions. a textbook of rheumatology. Baltimore: Lippincott, Williams & Wilkins; 2005. p. 2199\u2013226."},{"key":"347_CR2","first-page":"351","volume-title":"Best practice and research clinical rheumatology","author":"J Martel-Pelletier","year":"2008","unstructured":"Martel-Pelletier J, Boileau C, Pelletier J-P, Roughley P. Cartilage in normal and osteoarthritis conditions. In: Pap T, editor. Best practice and research clinical rheumatology. East Sussex: Rapid Medical Media; 2008. p. 351\u201384."},{"key":"347_CR3","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F","volume":"44","author":"JP Pelletier","year":"2001","unstructured":"Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001;44:1237\u201347.","journal-title":"Arthritis Rheum"},{"key":"347_CR4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.reprotox.2008.10.001","volume":"27","author":"BD Abbott","year":"2009","unstructured":"Abbott BD. Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol. 2009;27:246\u201357.","journal-title":"Reprod Toxicol"},{"key":"347_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.03.008","volume":"205","author":"JC Fruchart","year":"2009","unstructured":"Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009;205:1\u20138.","journal-title":"Atherosclerosis"},{"key":"347_CR6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bbalip.2007.02.004","volume":"1771","author":"L Michalik","year":"2007","unstructured":"Michalik L, Wahli W. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta. 2007;1771:991\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"347_CR7","first-page":"780452","volume":"2008","author":"MG Hall","year":"2008","unstructured":"Hall MG, Quignodon L, Desvergne B. Peroxisome proliferator-activated receptor beta\/delta in the brain: facts and hypothesis. PPAR Res. 2008;2008:780452.","journal-title":"PPAR Res"},{"key":"347_CR8","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1073\/pnas.92.17.7921","volume":"92","author":"Y Zhu","year":"1995","unstructured":"Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, et\u00a0al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA. 1995;92:7921\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"347_CR9","doi-asserted-by":"crossref","first-page":"18779","DOI":"10.1074\/jbc.272.30.18779","volume":"272","author":"L Fajas","year":"1997","unstructured":"Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, et\u00a0al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem. 1997;272:18779\u201389.","journal-title":"J Biol Chem"},{"key":"347_CR10","first-page":"679137","volume":"2008","author":"MC Cho","year":"2008","unstructured":"Cho MC, Lee K, Paik SG, Yoon DY. Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders. PPAR Res. 2008;2008:679137.","journal-title":"PPAR Res"},{"key":"347_CR11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1253\/circj.CJ-08-1071","volume":"73","author":"H Takano","year":"2009","unstructured":"Takano H, Komuro I. Peroxisome proliferator-activated receptor gamma and cardiovascular diseases. Circ J. 2009;73:214\u201320.","journal-title":"Circ J"},{"key":"347_CR12","doi-asserted-by":"crossref","first-page":"704165","DOI":"10.1155\/2008\/704165","volume":"2008","author":"HA Elrod","year":"2008","unstructured":"Elrod HA, Sun SY. PPARgamma and apoptosis in cancer. PPAR Res. 2008;2008:704165.","journal-title":"PPAR Res"},{"key":"347_CR13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.imbio.2008.07.015","volume":"213","author":"A Szanto","year":"2008","unstructured":"Szanto A, Nagy L. The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology. 2008;213:789\u2013803.","journal-title":"Immunobiology"},{"key":"347_CR14","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1074\/jbc.M610153200","volume":"282","author":"M Kapoor","year":"2007","unstructured":"Kapoor M, Kojima F, Qian M, Yang L, Crofford LJ. Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway. J Biol Chem. 2007;282:5356\u201366.","journal-title":"J Biol Chem"},{"key":"347_CR15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.plefa.2006.11.006","volume":"76","author":"M Kapoor","year":"2007","unstructured":"Kapoor M, Kojima F, Yang L, Crofford LJ. Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids. 2007;76:103\u201312.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"347_CR16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0092-8674(95)90194-9","volume":"83","author":"SA Kliewer","year":"1995","unstructured":"Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995;83:813\u20139.","journal-title":"Cell"},{"key":"347_CR17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0092-8674(00)81574-3","volume":"93","author":"L Nagy","year":"1998","unstructured":"Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93:229\u201340.","journal-title":"Cell"},{"key":"347_CR18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0092-8674(95)90193-0","volume":"83","author":"BM Forman","year":"1995","unstructured":"Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803\u201312.","journal-title":"Cell"},{"key":"347_CR19","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1073\/pnas.0408384102","volume":"102","author":"FJ Schopfer","year":"2005","unstructured":"Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, et\u00a0al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci USA. 2005;102:2340\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"347_CR20","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953\u20136.","journal-title":"J Biol Chem"},{"key":"347_CR21","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2174\/156802608786413474","volume":"8","author":"N Cho","year":"2008","unstructured":"Cho N, Momose Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem. 2008;8:1483\u2013507.","journal-title":"Curr Top Med Chem"},{"key":"347_CR22","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1074\/jbc.272.6.3406","volume":"272","author":"JM Lehmann","year":"1997","unstructured":"Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272:3406\u201310.","journal-title":"J Biol Chem"},{"key":"347_CR23","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2165\/00003495-200868150-00005","volume":"68","author":"AJ Krentz","year":"2008","unstructured":"Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs. 2008;68:2131\u201362.","journal-title":"Drugs"},{"key":"347_CR24","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/ar2151","volume":"9","author":"H Afif","year":"2007","unstructured":"Afif H, Benderdour M, Mfuna-Endam L, Martel-Pelletier J, Pelletier JP, Duval N, et\u00a0al. Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is downregulated by interleukin-1beta in articular chondrocytes. Arthritis Res Ther. 2007;9:R31.","journal-title":"Arthritis Res Ther"},{"key":"347_CR25","doi-asserted-by":"crossref","first-page":"12243","DOI":"10.1074\/jbc.275.16.12243","volume":"275","author":"K Bordji","year":"2000","unstructured":"Bordji K, Grillasca JP, Gouze JN, Magdalou J, Schohn H, Keller JM, et\u00a0al. Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes. J Biol Chem. 2000;275:12243\u201350.","journal-title":"J Biol Chem"},{"key":"347_CR26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.joca.2003.11.008","volume":"12","author":"H Dumond","year":"2004","unstructured":"Dumond H, Presle N, Pottie P, Pacquelet S, Terlain B, Netter P, et\u00a0al. Site specific changes in gene expression and cartilage metabolism during early experimental osteoarthritis. Osteoarthritis Cartil. 2004;12:284\u201395.","journal-title":"Osteoarthritis Cartil"},{"key":"347_CR27","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/joca.2002.0835","volume":"10","author":"H Fahmi","year":"2002","unstructured":"Fahmi H, Pelletier JP, Mineau F, Martel-Pelletier J. 15d-PGJ(2) is acting as a \u2018dual agent\u2019 on the regulation of COX-2 expression in human osteoarthritic chondrocytes. Osteoarthritis Cartil. 2002;10:845\u20138.","journal-title":"Osteoarthritis Cartil"},{"key":"347_CR28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/1529-0131(200103)44:3<595::AID-ANR108>3.0.CO;2-8","volume":"44","author":"H Fahmi","year":"2001","unstructured":"Fahmi H, Di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum. 2001;44:595\u2013607.","journal-title":"Arthritis Rheum"},{"key":"347_CR29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0014-5793(01)02614-X","volume":"501","author":"S Boyault","year":"2001","unstructured":"Boyault S, Simonin MA, Bianchi A, Compe E, Liagre B, Mainard D, et\u00a0al. 15-Deoxy-delta12, 14-PGJ2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. FEBS Lett. 2001;501:24\u201330.","journal-title":"FEBS Lett"},{"key":"347_CR30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.febslet.2004.06.090","volume":"572","author":"S Boyault","year":"2004","unstructured":"Boyault S, Bianchi A, Moulin D, Morin S, Francois M, Netter P, et\u00a0al. 15-Deoxy-delta(12, 14)-prostaglandin J(2) inhibits IL-1beta-induced IKK enzymatic activity and IkappaBalpha degradation in rat chondrocytes through a PPARgamma-independent pathway. FEBS Lett. 2004;572:33\u201340.","journal-title":"FEBS Lett"},{"key":"347_CR31","first-page":"887","volume":"32","author":"X Li","year":"2005","unstructured":"Li X, Afif H, Cheng S, Martel-Pelletier J, Pelletier JP, Ranger P, et\u00a0al. Expression and regulation of microsomal prostaglandin E synthase-1 in human osteoarthritic cartilage and chondrocytes. J Rheumatol. 2005;32:887\u201395.","journal-title":"J Rheumatol"},{"key":"347_CR32","first-page":"561","volume":"43","author":"D Moulin","year":"2006","unstructured":"Moulin D, Poleni PE, Kirchmeyer M, Sebillaud S, Koufany M, Netter P, et\u00a0al. Effect of peroxisome proliferator activated receptor (PPAR)gamma agonists on prostaglandins cascade in joint cells. Biorheology. 2006;43:561\u201375.","journal-title":"Biorheology"},{"key":"347_CR33","doi-asserted-by":"crossref","first-page":"R1325","DOI":"10.1186\/ar1830","volume":"7","author":"A Bianchi","year":"2005","unstructured":"Bianchi A, Moulin D, Sebillaud S, Koufany M, Galteau MM, Netter P, et\u00a0al. Contrasting effects of peroxisome-proliferator-activated receptor (PPAR)gamma agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes: evidence for PPARgamma-independent inhibition by 15-deoxy-Delta12, 14prostaglandin J2. Arthritis Res Ther. 2005;7:R1325\u201337.","journal-title":"Arthritis Res Ther"},{"key":"347_CR34","doi-asserted-by":"crossref","first-page":"28411","DOI":"10.1074\/jbc.M312708200","volume":"279","author":"M Francois","year":"2004","unstructured":"Francois M, Richette P, Tsagris L, Raymondjean M, Fulchignoni-Lataud MC, Forest C, et\u00a0al. Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element. J Biol Chem. 2004;279:28411\u20138.","journal-title":"J Biol Chem"},{"key":"347_CR35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.20900","volume":"52","author":"M Sabatini","year":"2005","unstructured":"Sabatini M, Lesur C, Thomas M, Chomel A, Anract P, de Nanteuil G, et\u00a0al. Effect of inhibition of matrix metalloproteinases on cartilage loss in\u00a0vitro and in a guinea pig model of osteoarthritis. Arthritis Rheum. 2005;52:171\u201380.","journal-title":"Arthritis Rheum"},{"key":"347_CR36","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/1529-0131(200105)44:5<1096::AID-ANR190>3.0.CO;2-6","volume":"44","author":"KS Mix","year":"2001","unstructured":"Mix KS, Mengshol JA, Benbow U, Vincenti MP, Sporn MB, Brinckerhoff CE. A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum. 2001;44:1096\u2013104.","journal-title":"Arthritis Rheum"},{"key":"347_CR37","doi-asserted-by":"crossref","first-page":"22399","DOI":"10.1074\/jbc.M314118200","volume":"279","author":"B Relic","year":"2004","unstructured":"Relic B, Benoit V, Franchimont N, Ribbens C, Kaiser MJ, Gillet P, et\u00a0al. 15-Deoxy-delta12, 14-prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts. J Biol Chem. 2004;279:22399\u2013403.","journal-title":"J Biol Chem"},{"key":"347_CR38","doi-asserted-by":"crossref","first-page":"37939","DOI":"10.1074\/jbc.M402424200","volume":"3","author":"ZZ Shan","year":"2004","unstructured":"Shan ZZ, Masuko-Hongo K, Dai SM, Nakamura H, Kato T, Nishioka K. A potential role of 15-deoxy-delta12, 14-prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis. J Biol Chem. 2004;3:37939\u201350.","journal-title":"J Biol Chem"},{"key":"347_CR39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.plefa.2007.08.001","volume":"77","author":"J Wittwer","year":"2007","unstructured":"Wittwer J, Hersberger M. The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot Essent Fatty Acids. 2007;77:67\u201377.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"347_CR40","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1073\/pnas.94.12.6148","volume":"94","author":"AR Brash","year":"1997","unstructured":"Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci USA. 1997;94:6148\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"key":"347_CR41","doi-asserted-by":"crossref","first-page":"R44","DOI":"10.1186\/ar2652","volume":"11","author":"N Chabane","year":"2009","unstructured":"Chabane N, Zayed N, Benderdour M, Martel-Pelletier J, Pelletier JP, Duval N, et\u00a0al. Human articular chondrocytes express 15-lipoxygenase-1 and -2: potential role in osteoarthritis. Arthritis Res Ther. 2009;11:R44.","journal-title":"Arthritis Res Ther"},{"key":"347_CR42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0090-6980(02)00042-4","volume":"68\u201369","author":"Y Urade","year":"2002","unstructured":"Urade Y, Eguchi N. Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. Prostaglandins Other Lipid Mediat. 2002;68\u201369:375\u201382.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"347_CR43","doi-asserted-by":"crossref","first-page":"15789","DOI":"10.1074\/jbc.272.25.15789","volume":"272","author":"T Tanaka","year":"1997","unstructured":"Tanaka T, Urade Y, Kimura H, Eguchi N, Nishikawa A, Hayaishi O. Lipocalin-type prostaglandin D synthase (beta-trace) is a newly recognized type of retinoid transporter. J Biol Chem. 1997;272:15789\u201395.","journal-title":"J Biol Chem"},{"key":"347_CR44","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1471-4159.2006.03753.x","volume":"97","author":"I Mohri","year":"2006","unstructured":"Mohri I, Taniike M, Okazaki I, Kagitani-Shimono K, Aritake K, Kanekiyo T, et\u00a0al. Lipocalin-type prostaglandin D synthase is up-regulated in oligodendrocytes in lysosomal storage diseases and binds gangliosides. J Neurochem. 2006;97:641\u201351.","journal-title":"J Neurochem"},{"key":"347_CR45","doi-asserted-by":"crossref","first-page":"R146","DOI":"10.1186\/ar2581","volume":"10","author":"N Zayed","year":"2008","unstructured":"Zayed N, Li X, Chabane N, Benderdour M, Martel-Pelletier J, Pelletier JP, et\u00a0al. Increased expression of lipocalin-type prostaglandin D2 synthase in osteoarthritic cartilage. Arthritis Res Ther. 2008;10:R146.","journal-title":"Arthritis Res Ther"},{"key":"347_CR46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1006\/jaut.2001.0542","volume":"17","author":"JD Ji","year":"2001","unstructured":"Ji JD, Cheon H, Jun JB, Choi SJ, Kim YR, Lee YH, et\u00a0al. Effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. J Autoimmun. 2001;17:215\u201321.","journal-title":"J Autoimmun"},{"key":"347_CR47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2249.2002.01876.x","volume":"129","author":"S Yamasaki","year":"2002","unstructured":"Yamasaki S, Nakashima T, Kawakami A, Miyashita T, Ida H, Migita K, et\u00a0al. Functional changes in rheumatoid fibroblast-like synovial cells through activation of peroxisome proliferator-activated receptor gamma-mediated signalling pathway. Clin Exp Immunol. 2002;129:379\u201384.","journal-title":"Clin Exp Immunol"},{"key":"347_CR48","first-page":"C125","volume":"282","author":"MA Simonin","year":"2002","unstructured":"Simonin MA, Bordji K, Boyault S, Bianchi A, Gouze E, Becuwe P, et\u00a0al. PPAR-gamma ligands modulate effects of LPS in stimulated rat synovial fibroblasts. Am J Physiol Cell Physiol. 2002;282:C125\u201333.","journal-title":"Am J Physiol Cell Physiol"},{"key":"347_CR49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/joca.2001.0485","volume":"10","author":"H Fahmi","year":"2002","unstructured":"Fahmi H, Pelletier JP, Di Battista JA, Cheung HS, Fernandes J, Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma acitvators inhibit MMP-1 production in human synovial fibroblasts by reducing the activity of the activator protein 1. Osteoarthritis Cartil. 2002;10:100\u20138.","journal-title":"Osteoarthritis Cartil"},{"key":"347_CR50","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/art.20714","volume":"52","author":"K Farrajota","year":"2005","unstructured":"Farrajota K, Cheng S, Martel-Pelletier J, Afif H, Pelletier JP, Li X, et\u00a0al. Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12, 14-prostaglandin J2 through a histone deacetylase-independent mechanism. Arthritis Rheum. 2005;52:94\u2013104.","journal-title":"Arthritis Rheum"},{"key":"347_CR51","doi-asserted-by":"crossref","first-page":"22057","DOI":"10.1074\/jbc.M402828200","volume":"279","author":"S Cheng","year":"2004","unstructured":"Cheng S, Afif H, Martel-Pelletier J, Pelletier JP, Li X, Farrajota K, et\u00a0al. Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1. J Biol Chem. 2004;279:22057\u201365.","journal-title":"J Biol Chem"},{"key":"347_CR52","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1006\/bbrc.2001.4847","volume":"283","author":"Y Tsubouchi","year":"2001","unstructured":"Tsubouchi Y, Kawahito Y, Kohno M, Inoue K, Hla T, Sano H. Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-Delta(12, 14)-prostaglandin J2. Biochem Biophys Res Commun. 2001;283:750\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"347_CR53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1172\/JCI9652","volume":"106","author":"Y Kawahito","year":"2000","unstructured":"Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, et\u00a0al. 15-Deoxy-delta(12, 14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest. 2000;106:189\u201397.","journal-title":"J Clin Invest"},{"key":"347_CR54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/jpet.302.1.18","volume":"302","author":"R Yamazaki","year":"2002","unstructured":"Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002;302:18\u201325.","journal-title":"J Pharmacol Exp Ther"},{"key":"347_CR55","doi-asserted-by":"crossref","first-page":"9676","DOI":"10.1074\/jbc.M104560200","volume":"277","author":"A Sugawara","year":"2002","unstructured":"Sugawara A, Uruno A, Kudo M, Ikeda Y, Sato K, Taniyama Y, et\u00a0al. Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells. J Biol Chem. 2002;277:9676\u201383.","journal-title":"J Biol Chem"},{"key":"347_CR56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1074-7613(04)00030-5","volume":"20","author":"LH Wang","year":"2004","unstructured":"Wang LH, Yang XY, Zhang X, Huang J, Hou J, Li J, et\u00a0al. Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells. Immunity. 2004;20:205\u201318.","journal-title":"Immunity"},{"key":"347_CR57","doi-asserted-by":"crossref","first-page":"33201","DOI":"10.1074\/jbc.C000517200","volume":"275","author":"Y Kodera","year":"2000","unstructured":"Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y, Kato S. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J Biol Chem. 2000;275:33201\u20134.","journal-title":"J Biol Chem"},{"key":"347_CR58","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/417563a","volume":"417","author":"K Ge","year":"2002","unstructured":"Ge K, Guermah M, Yuan CX, Ito M, Wallberg AE, Spiegelman BM, et\u00a0al. Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis. Nature. 2002;417:563\u20137.","journal-title":"Nature"},{"key":"347_CR59","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/jcb.10397","volume":"88","author":"FD Urnov","year":"2003","unstructured":"Urnov FD. Chromatin remodeling as a guide to transcriptional regulatory networks in mammals. J Cell Biochem. 2003;88:684\u201394.","journal-title":"J Cell Biochem"},{"key":"347_CR60","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/nsmb1337","volume":"14","author":"SR Bhaumik","year":"2007","unstructured":"Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol. 2007;14:1008\u201316.","journal-title":"Nat Struct Mol Biol"},{"key":"347_CR61","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1128\/MCB.20.18.6891-6903.2000","volume":"20","author":"K Ito","year":"2000","unstructured":"Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol. 2000;20:6891\u2013903.","journal-title":"Mol Cell Biol"},{"key":"347_CR62","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.1073\/pnas.132556899","volume":"99","author":"K Ito","year":"2002","unstructured":"Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, et\u00a0al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA. 2002;99:8921\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"347_CR63","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nature03988","volume":"437","author":"G Pascual","year":"2005","unstructured":"Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et\u00a0al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 2005;437:759\u201363.","journal-title":"Nature"},{"key":"347_CR64","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/art.20792","volume":"52","author":"T Kobayashi","year":"2005","unstructured":"Kobayashi T, Notoya K, Naito T, Unno S, Nakamura A, Martel-Pelletier J, et\u00a0al. Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis Rheum. 2005;52:479\u201387.","journal-title":"Arthritis Rheum"},{"key":"347_CR65","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/art.22726","volume":"56","author":"C Boileau","year":"2007","unstructured":"Boileau C, Martel-Pelletier J, Fahmi H, Mineau F, Boily M, Pelletier JP. The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in\u00a0vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. Arthritis Rheum. 2007;56:2288\u201398.","journal-title":"Arthritis Rheum"},{"key":"347_CR66","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1002\/art.11351","volume":"48","author":"S Cuzzocrea","year":"2003","unstructured":"Cuzzocrea S, Mazzon E, Dugo L, Patel NS, Serraino I, Di Paola R, et\u00a0al. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum. 2003;48:3544\u201356.","journal-title":"Arthritis Rheum"},{"key":"347_CR67","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/ar2354","volume":"10","author":"M Koufany","year":"2008","unstructured":"Koufany M, Moulin D, Bianchi A, Muresan M, Sebillaud S, Netter P, et\u00a0al. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. Arthritis Res Ther. 2008;10:R6.","journal-title":"Arthritis Res Ther"},{"key":"347_CR68","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/ar1856","volume":"8","author":"T Tomita","year":"2006","unstructured":"Tomita T, Kakiuchi Y, Tsao PS. THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis. Arthritis Res Ther. 2006;8:R7.","journal-title":"Arthritis Res Ther"},{"key":"347_CR69","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/rheumatology\/ken398","volume":"48","author":"PF Sumariwalla","year":"2009","unstructured":"Sumariwalla PF, Palmer CD, Pickford LB, Feldmann M, Foxwell BM, Brennan FM. Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717. Rheumatology (Oxford). 2009;48:32\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"347_CR70","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1172\/JCI13202","volume":"108","author":"K Setoguchi","year":"2001","unstructured":"Setoguchi K, Misaki Y, Terauchi Y, Yamauchi T, Kawahata K, Kadowaki T, et\u00a0al. Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J Clin Invest. 2001;108:1667\u201375.","journal-title":"J Clin Invest"},{"key":"347_CR71","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.2337\/diabetes.51.8.2341","volume":"51","author":"M Stumvoll","year":"2002","unstructured":"Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes. 2002;51:2341\u20137.","journal-title":"Diabetes"},{"key":"347_CR72","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s001250100629","volume":"44","author":"J Ek","year":"2001","unstructured":"Ek J, Andersen G, Urhammer SA, Hansen L, Carstensen B, Borch-Johnsen K, et\u00a0al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia. 2001;44:1170\u20136.","journal-title":"Diabetologia"},{"key":"347_CR73","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00125-003-1323-1","volume":"47","author":"AS Doney","year":"2004","unstructured":"Doney AS, Fischer B, Cecil JE, Boylan K, McGuigan FE, Ralston SH, et\u00a0al. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia. 2004;47:555\u20138.","journal-title":"Diabetologia"},{"key":"347_CR74","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1161\/01.ATV.0000068680.19521.34","volume":"23","author":"PM Ridker","year":"2003","unstructured":"Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, et\u00a0al. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23:859\u201363.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"347_CR75","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1210\/jc.2003-032120","volume":"89","author":"T Temelkova-Kurktschiev","year":"2004","unstructured":"Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, Zawadzki C, Haulon S, Kubaszek A, et\u00a0al. Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab. 2004;89:4238\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"347_CR76","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/hmg\/7.3.435","volume":"7","author":"A Meirhaeghe","year":"1998","unstructured":"Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, et\u00a0al. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet. 1998;7:435\u201340.","journal-title":"Hum Mol Genet"},{"key":"347_CR77","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0008-6363(99)00256-4","volume":"44","author":"XL Wang","year":"1999","unstructured":"Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor gamma C161\u00a0\u2192\u00a0T polymorphism and coronary artery disease. Cardiovasc Res. 1999;44:588\u201394.","journal-title":"Cardiovasc Res"},{"key":"347_CR78","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1034\/j.1399-0004.2003.00154.x","volume":"64","author":"J Song","year":"2003","unstructured":"Song J, Sakatsume M, Narita I, Goto S, Omori K, Takada T, et\u00a0al. Peroxisome proliferator-activated receptor gamma C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy. Clin Genet. 2003;64:398\u2013403.","journal-title":"Clin Genet"},{"key":"347_CR79","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.exger.2004.03.034","volume":"39","author":"M Barbieri","year":"2004","unstructured":"Barbieri M, Bonafe M, Rizzo MR, Ragno E, Olivieri F, Marchegiani F, et\u00a0al. Gender specific association of genetic variation in peroxisome proliferator-activated receptor (PPAR)gamma-2 with longevity. Exp Gerontol. 2004;39:1095\u2013100.","journal-title":"Exp Gerontol"},{"key":"347_CR80","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/ard.2006.051904","volume":"65","author":"S Cheng","year":"2006","unstructured":"Cheng S, Afif H, Martel-Pelletier J, Benderdour M, Pelletier JP, Hilal G, et\u00a0al. Association of polymorphisms in the peroxisome proliferator-activated receptor gamma gene and osteoarthritis of the knee. Ann Rheum Dis. 2006;65:1394\u20137.","journal-title":"Ann Rheum Dis"},{"key":"347_CR81","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00296-005-0013-3","volume":"26","author":"A El-Sohemy","year":"2006","unstructured":"El-Sohemy A, Cornelis MC, Park YW, Bae SC. Catalase and PPARgamma2 genotype and risk of rheumatoid arthritis in Koreans. Rheumatol Int. 2006;26:388\u201392.","journal-title":"Rheumatol Int"},{"key":"347_CR82","first-page":"1631","volume":"33","author":"C Butt","year":"2006","unstructured":"Butt C, Gladman D, Rahman P. PPAR-gamma gene polymorphisms and psoriatic arthritis. J Rheumatol. 2006;33:1631\u20133.","journal-title":"J Rheumatol"},{"key":"347_CR83","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1006\/bbrc.1999.0896","volume":"260","author":"S Ogawa","year":"1999","unstructured":"Ogawa S, Urano T, Hosoi T, Miyao M, Hoshino S, Fujita M, et\u00a0al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun. 1999;260:122\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"347_CR84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00198-009-0965-3","volume":"21","author":"J Tamaki","year":"2010","unstructured":"Tamaki J, Iki M, Morita A, Ikeda Y, Sato Y, Kajita E, et\u00a0al. Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study. Osteoporos Int. 2010;21:321\u20139.","journal-title":"Osteoporos Int"},{"key":"347_CR85","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ajog.2004.09.033","volume":"192","author":"EJ Rhee","year":"2005","unstructured":"Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, et\u00a0al. The effects of C161\u00a0\u2192\u00a0T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am J Obstet Gynecol. 2005;192:1087\u201393.","journal-title":"Am J Obstet Gynecol"},{"key":"347_CR86","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cca.2006.08.014","volume":"376","author":"A Casado-Diaz","year":"2007","unstructured":"Casado-Diaz A, Cuenca-Acevedo R, Quesada JM, Dorado G. Individual single tube genotyping and DNA pooling by allele-specific PCR to uncover associations of polymorphisms with complex diseases. Clin Chim Acta. 2007;376:155\u201362.","journal-title":"Clin Chim Acta"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10165-010-0347-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:25:10Z","timestamp":1646843110000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-010-0347-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,4]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["347"],"URL":"https:\/\/doi.org\/10.1007\/s10165-010-0347-x","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,4]]}}}